# BioNTech SE (BNTX)

> Source: Nexqual · https://nexqual.com/BNTX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, BioNTech SE (BNTX), nexqual.com/BNTX" · informational, not investment advice.

**Price:** USD 89.67 (-1.77% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 91.29 · day 89.03–92.73 · 52w 79.52–124 · market cap $22.5B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold BNTX (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 15 Form 4 filings, $89.8M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.29 on a 1–5 scale) (21 analysts), mean target USD 116.66 (range 76.03–144.05).
- Total return with dividends: 1Y -14.4% vs S&P 500 +14.9%; 5Y -67.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.76, revenue estimate $1.04B.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold BNTX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 0.18% | $342M | Added +0.0% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
15 of 15 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-08…2026-10-09 | Sahin Ugur | Chief Executive Officer | 63,209 | $5.9M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-10-07 | Sahin Ugur | Chief Executive Officer | 24,000 | $2.3M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05…2026-10-06 | Sahin Ugur | Chief Executive Officer | 93,000 | $9.0M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-10-01…2026-10-02 | Sahin Ugur | Chief Executive Officer | 34,000 | $3.3M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-29…2026-09-30 | Sahin Ugur | Chief Executive Officer | 66,000 | $6.5M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-25…2026-09-28 | Sahin Ugur | Chief Executive Officer | 61,000 | $6.0M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-23…2026-09-24 | Sahin Ugur | Chief Executive Officer | 69,000 | $6.8M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-21…2026-09-22 | Sahin Ugur | Chief Executive Officer | 79,000 | $7.9M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-17…2026-09-18 | Sahin Ugur | Chief Executive Officer | 64,000 | $6.2M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-15…2026-09-16 | Sahin Ugur | Chief Executive Officer | 49,000 | $4.7M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-11…2026-09-14 | Sahin Ugur | Chief Executive Officer | 86,000 | $8.4M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-10 | Sahin Ugur | Chief Executive Officer | 20,500 | $2.0M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-08…2026-09-09 | Sahin Ugur | Chief Executive Officer | 73,000 | $7.2M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-03…2026-09-04 | Sahin Ugur | Chief Executive Officer | 76,500 | $7.9M | 8.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-04-22 | Poetting Sierk | Chief Operating Officer | 50,000 | $5.5M | 11.1% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.29 on a 1–5 scale), 21 analysts; mean target USD 116.66 (low 76.03, high 144.05).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Canaccord Genuity | Target lowered | Buy | $136 → $132 |
| 2026-10-07 | Morgan Stanley | Target lowered | Overweight | $115 → $114 |
| 2026-09-08 | BMO Capital | Downgrade | Outperform → Market Perform | $128 → $105 |
| 2026-08-31 | Canaccord Genuity | Target lowered | Buy | $142 → $136 |
| 2026-08-05 | Citigroup | Target lowered | Buy | $130 → $125 |
| 2026-08-05 | Evercore ISI Group | Target lowered | Outperform | $135 → $130 |
| 2026-07-08 | Morgan Stanley | Target lowered | Overweight | $126 → $119 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -14.4% | -67.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -14.4% | -20.0% |
| Volatility (annualized) | 46.7% | 52.2% |
| Max drawdown | -29.7% (Jan 2026→Mar 2026) | -76.7% (Nov 2021→Jul 2024) |

## Peers (Biotechnology)
INCY (Incyte Corporation) USD 116.93 +3.08% · GMAB (Genmab A/S) USD 40 +1.09% · INSM (Insmed Incorporated) USD 95.06 +1.08% · ROIV (Roivant Sciences Ltd.) USD 37.45 +1.77% · ALNY (Alnylam Pharmaceuticals, Inc.) USD 227.28 +0.97% · EXEL (Exelixis, Inc.) USD 65.31 +1.13%

## More
Full page: https://nexqual.com/BNTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in BNTX's own 20-F filed 2026-03-10 (https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Manufacturing | "BioNTech iNeST Clinical Manufacturing (East Wing): We utilize our GMP-certified manufacturing facility at our" |
| Supplier | Nasdaq Stock Market | "Additionally, we rely on a provision in Nasdaq's Listed Company Manual that" |
| Partner | Pfizer (PFE) | "countries where it is commercializing our COVID-19 vaccine under our collaboration agreement with Pfizer for" |
| Partner | Therapeutics | "In April 2020, we entered into a Non-Exclusive License Agreement with Acuitas, or the Acuitas License" |
| Partner | REGENERON PHARMACEUTICALS, INC. (REGN) | "(10)In collaboration with Regeneron." |
| Partner | Ganymed Pharmaceuticals | "Under the TRON License Agreement, we and Ganymed must agree on which party will have the primary role in" |
| Partner | Germany | "capabilities of our partners, except in Germany and Türkiye." |
| Partner | Fosun Pharmaceutical Industrial Development | "Under our collaboration with Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, Fosun" |
| Partner | Siemens | "subsidiary, BioNTech RNA Pharmaceuticals GmbH, or BioNTech RNA, and Siemens announced a collaboration" |
| Partner | Ryvu Therapeutics | "prepayments for our collaborations with Ryvu Therapeutics S.A., Krakow, Poland, €5.5 million (€8.5 million as of" |
| Competitor | Moderna (MRNA) | "developed by Moderna, Inc. and Novavax, Inc. Our competitors pursuing vaccine candidates may have greater" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.76 | $0.66 | +15.4% | $1.04B | 5 |
| Next quarter (ends 2026-12-31) | $-0.84 | $-0.84 | +0.2% | $516.4M | 5 |
| Current fiscal year (ends 2026-12-31) | $-4.68 | $-4.26 | +9.9% | $1.78B | 10 |
| Next fiscal year (ends 2027-12-31) | $-4.81 | $-4.33 | +11.2% | $1.80B | 10 |